| Time course study | WB (6, 12, 24, and 72 h post-ROSC) | Sham (n = 4) | 0 |
| ACA (6 h, 12 h, 24 h, 72 h) (n = 16) | 3 (1 died at 12 h, 1 died at 15 h, and 1 died at 22 h post-ROSC) |
| Cellular localization (24 h post-ROSC) | Sham (n = 1), ACA (n = 1) | 0 |
| Toluidine blue staining (24 h post-ROSC) | Sham (n = 1) | 0 |
| ACA (n = 1) | 0 |
| Short-term outcome study (up to 7-day post ROSC) | Fluoro-Jade C staining | Sham (n = 6) | 0 |
| ACA + vehicle (n = 6) | 2 (1 at 24 h post-ROSC, 1 died at 48 h post-ROSC) |
| ACA + APC366 (50 μg) (n = 6) | 2 (1 died at 48 h post-ROSC, 1 died at 70 h post-ROSC) |
| ACA + APC366 (150) (n = 6) | 1 (died at 6 h post-ROSC) |
| ACA + AC55541 (30 μg) (n = 6) | 2 (1 died on 5th day post-ROSC, 1 died on 6th post-ROSC) |
| Long-term outcome study (30-day post-ROSC) | Fluoro-Jade C staining | Sham (n = 6) | 0 |
| ACA + vehicle (n = 6) | 0 |
| ACA + APC366 (50 μg) (n = 6) | 0 |
| Mechanism study (24 h post-ROSC) | Western blot | Sham (n = 6) | 0 |
| ACA + vehicle (n = 6) | 0 |
| ACA + APC366 (50 μg) (n = 6) | 0 |
| ACA + AC55541 (30 μg) (n = 6) | 0 |
| ACA + APC366 (50 μg) + AC55541 (30 μg) (n = 6) | 1 (died at 8 h post-ROSC) |
| ACA + AC55541 (30 μg) + SB203580 (300 μg) (n = 6) | 0 |
| | Mass spectrometry | APC366 (n = 1) | 0 |
| Total | 120 | 109 | 11 |
